Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 3131-year-old man comes to the clinic for a scheduled follow-up evaluation. Six months ago, he presented with a painless penile ulcer and a diffuse maculopapular rash involving his palms and soles. At that time, a rapid plasma reagin (RPR) test was reactive with a titer of 1:641:64, and a Treponema pallidum particle agglutination (TP-PA) test was positive. He was diagnosed with secondary syphilis and successfully treated with a single intramuscular injection of 2.42.4 million units of benzathine penicillin G. Today, the patient reports feeling well and notes that his rash resolved completely within a few weeks of treatment. He has no new sexual partners and has been consistently using condoms. Vital signs are within normal limits. Physical examination reveals clear skin with no active lesions, rashes, or lymphadenopathy. Neurologic examination shows no abnormalities. Which of the following is the most appropriate next step to evaluate the efficacy of this patient's treatment?

  1. A
    Repeat the Treponema pallidum particle agglutination test to ensure it has become nonreactive
  2. B
    Provide routine reassurance with no further laboratory testing since his clinical symptoms have resolved
  3. Repeat the rapid plasma reagin test to confirm at least a four-fold reduction in the titerAnswer
  4. D
    Perform a lumbar puncture to analyze cerebrospinal fluid to rule out asymptomatic neurosyphilis
  5. E
    Order magnetic resonance imaging of the brain to screen for central nervous system involvement

Answer

Repeat the rapid plasma reagin test to confirm at least a four-fold reduction in the titer.
The most appropriate next step in evaluating the efficacy of this patient's treatment is to repeat the rapid plasma reagin (RPR) test. Patients who are treated for primary or secondary syphilis must undergo clinical and serologic evaluation at 6 and 12 months following therapy. Treatment success is defined objectively by at least a four-fold decline in the quantitative nontreponemal titer (e.g., a drop from 1:641:64 to 1:161:16 or lower). If the titer fails to decrease appropriately or increases, it suggests either treatment failure or reinfection, prompting consideration for further evaluation (such as cerebrospinal fluid analysis) and re-treatment.

Step-by-Step Solution

1
Identify the patient's underlying diagnosis and recent intervention.
The patient was diagnosed with secondary syphilis 6 months ago and appropriately treated with intramuscular benzathine penicillin G.
Establishes the timeline and baseline data required to formulate an adequate follow-up and monitoring plan.
2
Determine the standard protocol for post-treatment monitoring of this disease.
Patients treated for primary or secondary syphilis require clinical and serologic evaluation at 6 and 12 months using quantitative nontreponemal tests (RPR or VDRL).
Treponemal tests (TP-PA, FTA-ABS) remain positive for life, whereas nontreponemal titers correlate with disease activity and treatment response.
3
Establish the expected laboratory outcome that indicates successful therapy.
A four-fold or greater decrease in the nontreponemal titer (e.g., from 1:641:64 to 1:161:16 or lower) at 6 to 12 months confirms an adequate response.
This objective metric definitively rules out treatment failure and guides decisions regarding possible re-treatment.

Key Concept

Post-treatment monitoring of syphilis requires quantitative nontreponemal testing (e.g., RPR) at 6 and 12 months to confirm an adequate serologic response, defined as at least a four-fold decline in titer.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic